Amenamevir

Amenamevir

Clinical data
Trade names	Amenalief
Other names	ASP-2151, ASP2151
ATC code	J05AX26 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N-(2,6-Dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
JSmol)	Interactive image
SMILES Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1
InChI InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29) Key:MNHNIVNAFBSLLX-UHFFFAOYSA-N

Amenamevir (trade name Amenalief) is an antiviral drug used for the treatment of shingles (herpes zoster).

It acts as an inhibitor of the zoster virus's helicase–primase complex.^[1][2] Amenamevir was approved in Japan for the treatment of shingles in 2017.^[3]

References